Cancer最新文献

{"title":"Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial","authors":"Michael Cecchini MD,&nbsp;Mary Jo Pilat PhD, MS, PA,&nbsp;Nataliya Uboha MD, PhD,&nbsp;Nilofer S. Azad MD,&nbsp;May Cho MD,&nbsp;Elizabeth J. Davis MD,&nbsp;Jordi Rodon Ahnert MD, PhD,&nbsp;Gabriel Tinoco MD,&nbsp;Geoffrey I. Shapiro MD, PhD,&nbsp;Simon Khagi MD,&nbsp;Benjamin Powers MD,&nbsp;Kristen Spencer DO,&nbsp;Roman Groisberg MD,&nbsp;Jan Drappatz MD,&nbsp;Li Chen PhD,&nbsp;Biswajit Das PhD,&nbsp;Xun Bao PhD,&nbsp;Jing Li PhD,&nbsp;Azeet Narayan PhD,&nbsp;Dennis Vu BS,&nbsp;Abhijit Patel MD, PhD,&nbsp;Monica Niger MD,&nbsp;Deborah Doroshow MD, PhD,&nbsp;Diane Durecki MS,&nbsp;Scott A. Boerner MS,&nbsp;Ranjit Bindra MD, PhD,&nbsp;Percy Ivy MD,&nbsp;Derek Shyr PhD,&nbsp;Yu Shyr PhD,&nbsp;Patricia M. LoRusso DO","doi":"10.1002/cncr.35755","DOIUrl":"https://doi.org/10.1002/cncr.35755","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neomorphic isocitrate dehydrogenase (<i>IDH</i>) mutations lead to the accumulation of 2-hydroxyglutarate (2-HG), an oncometabolite implicated in tumor progression via inhibitory effects on alpha-ketoglutarate. Moreover, mutant <i>IDH</i>–dependent accumulation of 2-HG results in homologous recombination deficiency (HRD), which preclinically renders tumors sensitive to poly(adenosine diphosphate ribose) polymerase inhibitors. Here, the results of the cholangiocarcinoma (CCA) arm of the National Cancer Institute (NCI) 10129 olaparib in <i>IDH</i>-mutant solid tumors basket trial are reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Olaparib 300 mg twice daily was evaluated in an open-label, phase 2 clinical trial for treatment-refractory <i>IDH</i>-mutant solid tumors. Patients in the <i>IDH</i>-mutant CCA arm enrolled in two cohorts: (1) IDH inhibitor (IDHi) pretreated and (2) IDHi untreated, with a primary end point of overall response rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>NCI 10129 enrolled 30 patients with <i>IDH</i>-mutant CCA with no objective responses seen, and recruitment was closed early. Median progression-free survival (PFS) was 2.4 months (95% CI, 1.9 to 6.5 months) and median overall survival was 12.9 months (95% CI, 6.3 months to not reached). Eight patients (27%) had clinical benefit (CB), with a PFS of ≥6 months. Patients with CB had lower baseline 2-HG levels compared to those without CB (1.4 vs. 5.9 µmol/L; <i>p</i> = .01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Olaparib does not have sufficient single-agent activity to warrant further development in <i>IDH</i>-mutant CCA. However, a subgroup of patients demonstrated CB, and exploratory analysis revealed this subgroup to be enriched for lower baseline 2-HG levels. Future clinical trials leveraging the HRD properties of <i>IDH</i> mutations are warranted with enhanced patient selection and novel combination therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study","authors":"Marlise R. Luskin MD, MSCE,&nbsp;Jun Yin PhD,&nbsp;Gerard Lozanski MD,&nbsp;Emily Curran MD,&nbsp;Gregory Malnassy PhD,&nbsp;Krzysztof Mrózek MD, PhD,&nbsp;Clara D. Bloomfield MD,&nbsp;Spero R. Cataland MD,&nbsp;Noreen Fulton BA,&nbsp;Jonathan Kolitz MD,&nbsp;Betsy Laplant MS,&nbsp;Oudom Kour MS,&nbsp;Bayard L. Powell MD,&nbsp;Ravi Vij MD,&nbsp;Eunice S. Wang MD, PhD,&nbsp;David Grinblatt MD,&nbsp;Richard M. Stone MD,&nbsp;Geoffrey L. Uy MD,&nbsp;Richard A. Larson MD,&nbsp;Wendy Stock MD","doi":"10.1002/cncr.35750","DOIUrl":"https://doi.org/10.1002/cncr.35750","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this phase 1/2 study (Cancer and Leukemia Group B [CALGB] 10102, NCT00061945), a course of single-agent alemtuzumab was intercalated into CALGB 19802 backbone chemotherapy after the third course of intensive chemotherapy in those who were CD52+ at diagnosis. Phase 1 tested three dose levels of subcutaneous alemtuzumab (10, 20, and 30 mg 3 times weekly for 4 weeks/12 doses) and demonstrated that 30 mg was tolerable. Phase 2 established feasibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study enrolled 295 evaluable patients (115 in phase 1, 180 in phase 2); 206 (69.8%) were CD52+. Among evaluable CD52+ patients, 43.7% (90/206) completed the first three treatment modules; 97.8% (88 of 90) were treated with alemtuzumab. Alemtuzumab was associated with cytomegalovirus viremia, which occurred in 23.3% (14 of 60) of patients during and 29.2% (19 of 65) after alemtuzumab treatment. With a median follow-up of 101.2 months, median overall survival (OS) was 26.3 months (3-year rate, 44%; 5-year rate, 36%; 10-year rate, 31%). Landmark analysis at the start of the fourth course of treatment demonstrated no difference in OS or disease-free survival between patients who did and who did not receive alemtuzumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Alemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial toxicity: A ubiquitous condition in patients with cancer","authors":"Joseph M. Unger PhD","doi":"10.1002/cncr.35748","DOIUrl":"https://doi.org/10.1002/cncr.35748","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community-engaged adaptation of ACCESS: A navigator-led early palliative care intervention for Black and Latina women with advanced breast cancer","authors":"Melissa Mazor PhD, MS, RN,&nbsp;Jenny J. Lin MD, MPH,&nbsp;Cardinale Smith MD, PhD,&nbsp;William E. Rosa PhD, MBE, MS,&nbsp;Dolores Moorehead APCC,&nbsp;Rebecca M. Boorstin BA,&nbsp;Jordan Karpin BS,&nbsp;Alex Nelson BS,&nbsp;Marie A. Bakitas DNSc, RN, AOCN, FPCN, FAAN,&nbsp;Sarah Miller PsyD,&nbsp;J. Nicholas Odom PhD, RN, ACHPN, FPCN, FAAN","doi":"10.1002/cncr.35745","DOIUrl":"https://doi.org/10.1002/cncr.35745","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Disparities in early palliative care (PC) access for Black and Latina women with advanced breast cancer (ABC) persist. This study elicited qualitative feedback from patients with ABC and health professionals to adapt a community navigator-led early PC program called ACCESS to improve PC access and supportive care outcomes for Black and Latina women with ABC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a formative evaluation study using a community-engaged approach. Guided by a community advisory board, qualitative interviews were conducted with Black and Latina women with ABC (<i>N</i> = 20) and interdisciplinary health professionals and patient navigators (<i>N</i> = 20) to elicit feedback on the content, delivery, and format of ACCESS, a navigator-delivered early PC intervention to improve PC access and outcomes. Thematic analysis was conducted using inductive coding followed by deductive analysis using the Consolidated Framework for Implementation Research framework to guide intervention adaptation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Findings indicate that ACCESS addresses the early PC needs of Black and Latina women with ABC, yet needs to embed flexibility per patient preferences. Additionally, PC should be introduced as supportive care to enhance acceptability. Navigators emphasized fostering awareness and access to resources, which are crucial for patients' well-being. Strong interdisciplinary relationships and care coordination are essential for embedding ACCESS. Recognizing patient individuality, addressing historical and cultural factors, and ensuring navigators are empathetic, well-trained, and culturally aligned with patients were highlighted as pivotal for the intervention's success.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings will inform the adaptation of ACCESS for feasibility and preliminary efficacy testing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to “Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?”","authors":"Henry C. Mandeville MBChB, MD(Res),&nbsp;Gianni Bisogno MD, PhD,&nbsp;Veronique Minard-Colin MD, PhD,&nbsp;Rita Alaggio MD,&nbsp;Myriam Ben-Arush MD,&nbsp;Cyrus Chargari MD, PhD,&nbsp;Beatrice Coppadoro BSc,&nbsp;Ross Craigie MBChB,&nbsp;Christine Devalck MD,&nbsp;Sima Ferman MD, PhD,&nbsp;Andrea Ferrari MD,&nbsp;Heidi Glosli MD,&nbsp;Raquel Hladun Alvaro MD,&nbsp;Marinka Hol MD, PhD,&nbsp;Peter Mudry MD,&nbsp;Daniel Orbach MD,&nbsp;Monica Ramos Albiac MD,&nbsp;Johannes H. M. Merks MD, PhD,&nbsp;Meriel E. M. Jenney MBChB, MD","doi":"10.1002/cncr.35744","DOIUrl":"https://doi.org/10.1002/cncr.35744","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION OF CONCERN: Mechanisms of Synthetic Serine Protease Inhibitor (FUT-175)-Mediated Cell Death","authors":"","doi":"10.1002/cncr.35718","DOIUrl":"https://doi.org/10.1002/cncr.35718","url":null,"abstract":"<p><b>EXPRESSION OF CONCERN</b>: T. Uwagawa, Z. Li, Z. Chang, Q. Xia, B. Peng, G. M. Sclabas, S. Ishiyama, M.-C. Hung, D. B. Evans, J. L. Abbruzzese, and P. J. Chiao, “Mechanisms of Synthetic Serine Protease Inhibitor (FUT-175)-Mediated Cell Death,” <i>Cancer</i> 109, no. 10 (2007): 2142-2153, https://doi.org/10.1002/cncr.22658.</p><p>This Expression of Concern is for the above article, published online on 04 April 2007 in Wiley Online Library (wileyonlinelibrary.com), and has been published by agreement between the journal Editor-in-Chief, Suresh S. Ramalingam; the American Cancer Society; and Wiley Periodicals LLC. The Expression of Concern has been published due to concerns raised by a third party regarding inconsistencies identified between Figure 1D and Figure 2D. The figures depict bands from the same experimental conditions and while the band of IκBα lane – 80 µg/ml FUT175 is identical in both figures, the corresponding β-actin loading control band is different.</p><p>The authors were informed about the concerns, but due to the time elapsed since publication, the raw data was not available. Without an explanation of the anomaly in the figure and in the absence of the original raw data, the journal team could not verify the authenticity of this figure. Although the inconsistencies found in the figures likely do not affect the results and the conclusions of this publication, the journal has decided to issue an Expression of Concern to inform the readers.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35718","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial practice changing?","authors":"Bart M. F. Penninx MD,&nbsp;Michael J. Samson MD,&nbsp;John-John B. Schnog MD, PhD","doi":"10.1002/cncr.35749","DOIUrl":"https://doi.org/10.1002/cncr.35749","url":null,"abstract":"<p>At the second interim analysis, the ENGOT-cx11/GOG-3047/KEYNOTE-A18 demonstrated an overall survival (OS) benefit after 36 months in stage III–IVa cervical cancer patients treated with chemoradiotherapy and concurrent pembrolizumab followed by 90 weeks of pembrolizumab as compared to placebo (82.6% vs. 74.8%, hazard ratio for death, 0.67 [confidence interval, 0.50–0.90]). Only 51 of 193 progressing patients in the control arm were exposed to immunotherapy after progressing. The reported OS benefit could be explained by suboptimal post-progression treatment in the control group. Even if pembrolizumab as administered in the ENGOT-cx11/GOG-3047/KEYNOTE-A18 was efficacious, the treatment duration is excessively long. The associated costs render it unattainable in the regions where burden of cervical cancer is highest. Based on these concerns, the findings at the interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 RCT should not change practice.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma: How much is enough?","authors":"Ewa Koscielniak MD,&nbsp;Thomas Klingebiel MD","doi":"10.1002/cncr.35743","DOIUrl":"https://doi.org/10.1002/cncr.35743","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 4","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143362267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New AI model shows promise for cancer diagnosis","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35715","DOIUrl":"10.1002/cncr.35715","url":null,"abstract":"&lt;p&gt;A new ChatGPT-like artificial intelligence (AI) model developed by researchers at Harvard Medical School outperforms other state-of-the-art AI methods by up to 36% in an array of diagnostic tasks across multiple forms of cancer. These tasks include the detection of cancer cells, the identification of a tumor’s origin, the prediction of patient outcomes, and the identification of the presence of genes and DNA patterns associated with treatment response.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;sup&gt;,&lt;/sup&gt;\u0000 &lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The Clinical Histopathology Imaging Evaluation Foundation (CHIEF) model achieved nearly 94% accuracy in cancer detection across 15 different databases containing 11 cancer types. Its accuracy increased to 96% when it was based on five biopsy data sets for multiple cancer types, which included esophageal, stomach, colon, and prostate cancers, and achieved more than 90% accuracy when it was based on previously unseen slides from surgically removed tumors of multiple cancers, which included colon, lung, breast, endometrial, and cervical cancers.&lt;/p&gt;&lt;p&gt;The model was trained on more than 60,000 whole-slide pathology images spanning 19 anatomical sites, and it works by reading digital slides of tumor tissues to detect cancer cells and predict a tumor’s molecular profile.&lt;/p&gt;&lt;p&gt;For predicting tumors’ molecular profiles, CHIEF successfully identified several important genes associated with cancer growth and suppression and predicted key genetic mutations related to a tumor’s potential response to targeted therapy. When tested on US Food and Drug Administration–approved targeted therapies (across 18 genes in 15 anatomic sites), the model was 96% accurate in detecting &lt;i&gt;EZH2&lt;/i&gt; in diffuse large B-cell lymphoma, 89% accurate in detecting &lt;i&gt;BRAF&lt;/i&gt; in thyroid cancer, and 91% accurate in detecting &lt;i&gt;NTRK1&lt;/i&gt; in head and neck cancers.&lt;/p&gt;&lt;p&gt;Using tumor histopathology images obtained at initial diagnosis, CHIEF also was able to predict patient survival and outperformed other AI models by 8% in its ability to distinguish between patients with longer- and shorter-term survival (for all cancer types) and by 10% in its ability to distinguish survival rates in patients with advanced cancers.&lt;/p&gt;&lt;p&gt;“The performance that the model was able to demonstrate across a diverse set of types and tasks was very impressive,” says Fei Wang, MD, professor of population health sciences and founding director of the Institute of Artificial Intelligence for Digital Health at Weill Cornell Medicine, who thinks that AI has huge potential to augment clinical tasks and improve patient care.&lt;/p&gt;&lt;p&gt;However, he underscores the need for rigorous prospective evaluations through clinical trials to better understand how these types of models work in the real world.&lt;/p&gt;&lt;p&gt;“The current model has not been tested in real-world clinical care settings, so it is not clear how robust the model will be with respect to real-world challenges, such as imaging quality, c","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35715","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143072945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Men face substantial lifelong risk of oral HPV infection","authors":"Mary Beth Nierengarten","doi":"10.1002/cncr.35714","DOIUrl":"10.1002/cncr.35714","url":null,"abstract":"&lt;p&gt;Men remain at risk of acquiring an oral human papillomavirus (HPV) infection throughout their lifetime, suggesting a benefit of HPV vaccination in men regardless of age according to a study published in &lt;i&gt;Nature Microbiology&lt;/i&gt;.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;It is well known that oral HPV infections, particularly those with high-risk genotypes, cause oropharyngeal cancer, with HPV-16 found in approximately 90% of all oropharyngeal cancer cases in men in the United States.&lt;/p&gt;&lt;p&gt;Less known is the natural history of oral HPV infection. The current study fills that gap by providing information on rates of newly acquired oral HPV infections and associated risk factors for acquiring HPV infections in a multinational cohort of more than 3000 men from the United States, Brazil, and Mexico who were followed for a median of 57 months.&lt;/p&gt;&lt;p&gt;The study found that the incident rate of any new oral oncogenic HPV infection was 2.4 per 1000 person-months, with men in the United States having a higher incidence (3.5 per 1000 person-months) than men in Brazil and Mexico (2.1 per 1000 person-months for both).&lt;/p&gt;&lt;p&gt;The highest incidence rate of any new oncogenic HPV infection by age was in the youngest cohort (18–24 years) at 2.9 per 1000 person-months, which was followed by 2.2 per 1000 person-months for those 25–32 or 33–41 years old and 2.5 per 1000 person-months for those 42 years old or older.&lt;/p&gt;&lt;p&gt;These incidence rates stayed constant over time, whether for any oncogenic HPV infection or by HPV genotype.&lt;/p&gt;&lt;p&gt;By country, men in the United States had a higher risk of acquiring any oncogenic HPV infection or an HPV-16 infection compared to those in Mexico. No difference was found between men in Brazil and men in Mexico.&lt;/p&gt;&lt;p&gt;Risk factors associated with a higher risk of HPV infection included higher education (13–15 years), alcohol consumption (&gt;60 alcoholic beverages in the past month), having only male sexual partners, a history of three or more female sexual partners, and more frequent performance of oral sex (at least seven times in the past 6 months). Men with one or more lost teeth due to oral disease also had a marginally elevated risk.&lt;/p&gt;&lt;p&gt;In all countries, no association was found between the risk of acquiring a new oral HPV infection and age, indicating that men may remain susceptible throughout their lifetime.&lt;/p&gt;&lt;p&gt;Zachary S. Zumsteg, MD, associate professor of the Department of Radiation Oncology at the Cedars–Sinai Samuel Oschin Comprehensive Cancer Institute, who specializes in head and neck cancers, says that the study provides strong evidence that men continue to be at risk of acquiring an oral HPV infection throughout life.&lt;/p&gt;&lt;p&gt;“One of the most surprising findings of this study is that the likelihood of acquiring an oral HPV infection was similar across age groups among the men enrolled in the study,” he says.&lt;/p&gt;&lt;p&gt;He notes that a prior cross-sectional study using data from the 2009–2010 National Health and Nutrition Examinat","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 3","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35714","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143072944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}